Insider Sell : Tg Therapeutics

TG Therapeutics, Inc. is a company that is fully integrated and in the commercial stage of development in the field of biopharmaceuticals. The company's main focus is on finding, developing, and marketing new treatments for diseases that affect B-cells. They have several drug candidates that are currently in clinical trials, including Ublituximab, TG-1701, and TG-1801. Ublituximab is a monoclonal antibody that targets a protein called CD20 and is being used to treat a range of B-cell diseases. TG-1701 is an inhibitor that targets a protein called BTK and is taken orally. TG-1801 is a bispecific antibody that targets both CD47 and CD19. The company is also looking for opportunities to collaborate with other companies and invest in new technologies and products.

Learn additional information about the organization.